Dataset from A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin

Primary Objective:

- To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c)
from baseline to endpoint (Week 24)

Secondary Objective:

- To assess the effect of the 2 lixisenatide regimens on:

- The percentage of participants who reached the target of HbA1c < 7% or ≤ 6.5% at
Week 24

- Fasting Plasma Glucose (FPG)

- 7-point Self-Monitored Plasma Glucose (SMPG) profiles

- Body weight

- To assess the safety and tolerability of the 2 lixisenatide regimens